

Cerebrospinal fluid alterations of the serotonin product, 5-hydroxyindolacetic acid, in neurological disorders

Elisa De Grandis · Mercedes Serrano · Belén Pérez-Dueñas · Aida Ormazábal · Raquel Montero · Edvige Veneselli · Mercè Pineda · Verónica González · Francesc Sanmartí · Carmen Fons · Anna Sans · Bru Cormand · Luis Puelles · Antonia Alonso · Jaime Campistol · Rafael Artuch · Angels García-Cazorla

Received: 24 May 2010 / Revised: 29 July 2010 / Accepted: 24 August 2010 / Published online: 18 September 2010
© SSIEM and Springer 2010

Abstract Although patients with low cerebrospinal fluid (CSF) serotonin metabolite levels have been reported, inborn errors of the rate-limiting enzyme of serotonin synthesis (tryptophan hydroxylase, TPH) have not been described so far. In this study we aimed to evaluate CSF alterations of the serotonin metabolite 5-hydroxyindolacetic acid (5-HIAA) in patients with neurological disorders and to explore a possible TPH deficiency in some of them. A total of 606 patients (286 males, 320 females, mean age 4 years and 6 months, SD 5 years and 7 months) underwent CSF analysis of neurotransmitter metabolites by reverse phase high performance liquid chromatography. Results were compared with values established in a control population. Patients' medical records were reviewed to determine diagnosis and clinical features. A primary defect of biogenic amines was genetically investigat-

ed in indicated patients. Low 5-HIAA was seen in 19.3%. Of these, 22.2% showed inborn errors of metabolism (mitochondrial disorders being the most frequent at 10.2% of low 5-HIAA patients) and neurogenetic conditions. Other relatively frequent conditions were pontocerebellar hypoplasia (4.3%), Rett syndrome (4.3%), and among congenital nonetiologically determined conditions, epilepsy including epileptic encephalopathies (26.4%), leukodystrophies (6.8%), and neuropsychiatric disturbances (4.2%). Mutational analysis of the *TPH2* gene, performed in five candidate patients, was negative. Although frequency of secondary alteration of 5-HIAA was relatively high in patients with neurological disorders, this finding was more frequently associated with some neurometabolic disorders, epileptic encephalopathies, and neuropsychiatric disturbances. No inborn

Communicated by: Sedel Frederic

Competing interest: None declared

E. De Grandis · M. Serrano · B. Pérez-Dueñas · M. Pineda · V. González · F. Sanmartí · C. Fons · A. Sans · J. Campistol · A. García-Cazorla (✉)
Neurology Department, Hospital Sant Joan de Deu, Barcelona, Spain
e-mail: agarcia@hsjdbcn.org

A. Ormazábal · R. Montero · R. Artuch
Department of Biochemistry, Hospital Sant Joan de Déu, Barcelona, Spain

L. Puelles · A. Alonso
Unidad de Neurobiología, Dpto. Anatomía Humana y Psicobiología, Facultad Medicina, Universidad Murcia, Murcia, Spain

E. De Grandis · E. Veneselli
Department of Child Neuropsychiatry, G. Gaslini Institute, University of Genoa, Genoa, Italy

B. Cormand
Departament de Genètica, Facultat de Biologia, Universitat de Barcelona, Barcelona, Spain

E. De Grandis · M. Serrano · B. Pérez-Dueñas · A. Ormazábal · R. Montero · M. Pineda · V. González · F. Sanmartí · C. Fons · A. Sans · B. Cormand · L. Puelles · A. Alonso · J. Campistol · R. Artuch · A. García-Cazorla
Biomedical Network of Research Centres on Rare Diseases (CIBER-ER), Instituto de Salud Carlos III, Madrid, Spain

errors of TPH were found. Due to serotonin's neurotrophic role and to ameliorate symptoms, a supplementary treatment with 5-hydroxytryptophan would seem advisable in these patients.

Introduction

Serotonin (5HT) projections in the brain are broad and diffuse. The dorsal raphe nucleus contains the largest 5HT neuron group, which projects to the forebrain and mesostriatum. Furthermore, serotonergic neurons are localized in the pineal gland, the substantia nigra, and the hypothalamus. 5HT is involved in the vegetative control of thirst, appetite, respiration, temperature control, and sleep-waking cycle, and modulates sensory and alpha motor neurons at the spinal cord. 5HT also affects neuronal proliferation, differentiation, migration, and synaptogenesis (Herlenius and Lagercrantz 2001).

5-Hydroxyindolacetic acid (5-HIAA) is the final metabolite of serotonin (5HT), and its measurement in cerebrospinal fluid (CSF) is thought to reflect the overall synaptic and extrasynaptic release activity of serotonergic neurons of the central nervous system (CNS). In childhood, the analysis of 5-HIAA, together with homovanillic acid (HVA), is the first step in the diagnosis of several inborn errors of biogenic amines and pterins. Although to date 10 enzyme deficiencies in the biogenic amine metabolic pathway have been described (Pons 2009), no pathogenetic mutations of the *TPH2* gene have as yet been found, in contrast to the dopaminergic-limiting enzyme tyrosine hydroxylase.

Secondary dopaminergic deficiencies have been broadly reported in adult neurology. By contrast, and although serotonergic innervation in the brain is more evenly distributed, its implication in different neurological disorders other than psychiatric diseases has scarcely been described. Previous studies showed secondary low 5-HIAA levels in infants with diverse neurological disorders and cortical brain atrophy (García-Cazorla et al. 2007), idiopathic adult-onset dystonia (Naumann et al. 1996), malignant epilepsies (Langlais et al. 1991), and dopa nonresponsive dystonia (Assmann et al. 2002). However, to date and to our knowledge, a large study determining the frequency and reviewing the possible causes of serotonergic alterations in patients with diverse neurological problems has not been reported.

Our aims were to study children and young adults with low CSF 5-HIAA, to determine the frequency of this alteration, and to learn whether this finding could be suggestive of a particular diagnosis or clinical picture. Moreover, in order to detect possible primary alterations of the biosynthetic 5HT pathway, a mutational analysis of the *TPH2* gene, encoding tryptophan hydroxylase 2 (the rate-

limiting enzyme for 5HT biosynthesis in CNS), was performed in some candidate children.

Methods

Patients

Over the last 7 years, 606 patients (286 males, 320 females; mean age 4.5 years; SD 5.6 years) presenting with neurological disorders whose etiology was initially unknown underwent a lumbar puncture at the Hospital Sant Joan de Déu, Barcelona.

Patients' medical records were reviewed to determine etiological diagnosis, the presence of epilepsy, EEG alterations, psychomotor delay, motor disturbances (including spasticity, ataxia, or movement disorders), micro- or macrocrania, and magnetic resonance imaging (MRI) findings. Patients with low 5-HIAA values and without a definite diagnosis were distributed into six clinical groups for descriptive purposes: (1) epilepsy, (2) epileptic encephalopathy, (3) motor disturbances, (4) leukodystrophy, (5) psychomotor delay, and (6) neuropsychiatric disturbances.

An epileptic encephalopathy was differentiated from a simple epileptic condition when frequent or severe seizures or subcontinuous paroxysmal interictal activity led to neurological deterioration. Patients with motor disturbances presented with the main clinical signs of spasticity, ataxia, or movement disorders, such as chorea or dystonia. Leukodystrophies were defined as cases characterized by diffuse involvement of the CNS white matter on MRI and with multiple neurological signs. In the group of patients affected by psychomotor delay, other neurological signs and symptoms could be present, but these features were mild or not specific. Finally, patients with neuropsychiatric disorders included those with severe autism spectrum disorders and behavioral disturbances.

All the patients underwent an exhaustive physical examination by an expert pediatric neurologist. Video recordings were obtained in subjects with motor disturbances. Brain MRI included T1- and T2-weighted images, and, when available, diffusion-weighted images and FLAIR (1.5 Tesla Signa EchoSpeed System, GE Medical Systems). Screening laboratory tests for diagnosis of inborn errors of metabolism (IEM) (lactate, pyruvate, ammonium, sialo-transferrin, and amino acids in plasma or serum; organic acids, glycosaminoglycans in urine) and karyotype were performed using standard procedures.

Samples were drawn in accordance with the Helsinki Declaration. The study was approved by the local ethics committee, and written informed consent was obtained from subjects or their parents.

CSF analysis

CSF samples were obtained by lumbar puncture according to previously described protocols (Hyland et al. 1993; Ormazabal et al. 2005). Biogenic amine metabolites (3-orthomethylidopa, 3-methoxy-4-hydroxyphenylglycol, HVA, 5-hydroxytryptophan, and 5-HIAA), pterins (neopterin and biopterin), and 5-methyltetrahydrofolate (5-MTHF) were analyzed by reverse phase high performance liquid chromatography (HPLC) with electrochemical and fluorescence detection, as previously reported. Results were compared with reference values established in our hospital (Ormazabal et al. 2005). Furthermore, glucose, proteins, lactate, and amino acids were determined by standard procedures.

Genetic analysis

A primary defect of biogenic amines or pterin metabolism was ruled out in patients with suggestive biochemical and clinical features by molecular analysis [tyrosine hydroxylase (TH), aromatic amino acid decarboxylase (AADC), and pterin deficiencies were investigated and are not included in the final study group if confirmed]. Regarding TPH deficiency, five patients with unexplained low values of 5-HIAA underwent direct sequencing of *TPH2* gene. The coding region, splice sites, 241 bp preceding the initiation codon, and 150 bp following the stop codon were amplified using a set of nine primer pairs (Bonsai Technologies Group; available upon request) and sequenced (ABI 3130 Genetic Analyzer, Applied Biosystems).

Statistical analysis

All analyses were performed using the SPSS 17.0 program. Chi-squared test was applied to search for the association between low CSF 5-HIAA levels and other biochemical (HVA, folate, neopterin, lactate) or clinical (presence of epilepsy, microcephaly, psychomotor delay, movement disorders) and neuroradiological data (white matter disturbances, atrophy, deep grey matter abnormalities, cerebellar or brainstem anomalies). A P value < 0.05 was considered to be statistically significant.

Results

One-hundred and seventeen patients (117/606; 19.3%) with different neurological disorders had low CSF 5-HIAA levels according to our reference values [62 (53%) were females and 55 (47%) males]. Mean age at lumbar puncture was 5.3 years (age range 1 month to 25 years; SD = 5.95 years). Low 5-HIAA levels were detected in every age

group when compared with reference ranges for that group (Fig. 1)

Biochemical features of the low 5-HIAA study group

5-HIAA deficit was the only CSF abnormality in 49.1% of patients, while the rest also presented other biochemical CSF abnormalities. HVA deficiency was demonstrated in 54/117 patients (46.2%), denoting a combination of serotonergic and dopaminergic disturbances. Low pterin levels were found in 15/114 patients and high levels in 9/114. Finally, CSF folate deficiency was present in 13 out of 112 cases with 5HT deficiency (11.6%). Seven out of 112 patients (6.3%) presented a combined deficiency of CSF 5-HIAA, HVA, and 5-MTHF values.

Clinical features of the 5-HIAA study group

Careful clinical follow-up of patients with low 5-HIAA allowed us to identify diverse diseases and conditions (Table 1). Eleven out of 117 patients (9.4%) turned out to have acquired CNS injuries. The other 106 patients (90.6%) presented genetic or congenital conditions: 31 (26.5%) had an epileptic condition of unknown etiology (19 had epileptic encephalopathy and 12 epilepsy), and 26 (22.2%) were affected with IEM and neurogenetic conditions. In particular nearly half of them (12 patients) were affected with mitochondrial disorders. The other half experienced diverse heterogeneous metabolic disorders. Other relatively frequent conditions were pontocerebellar




Fig. 1 5-HIAA levels in patients with neurological disorders compared with reference ranges for each age group

Table 1 Etiological classification of patients and 5-HIAA concentrations in CSF

Etiological classification	No. of patients	Cerebrospinal fluid 5-HIAA (nmol/l) individual values according to age range
Acquired CNS injuries	11	
Perinatal injury	3	A : 78; B: 149, 159
Encephalitis	2	A: 378; D: 56
Cerebrovascular disorder	2	A: 294; F: 58
Connatal cytomegalovirus	1	C: 81
Lymphoblastic lymphoma	1	E: 77
Celiac disease-associated ataxia	1	D: 48
Rheumatic chorea	1	D: 90
Genetic or congenital conditions etiologically determined	42	
Inborn errors of metabolism	26	
Mitochondrial disorders	12	B: 144, 167; C: 158, 149, 115, 152; E: 71, 64; F: 51, 59, 62, 43
Niemann Pick type C	3	C: 135; F: 45, 50
Alexander disease	3	D: 91; F: 28, 33
Organic acidurias (glutaric, argininosuccinic, urocanic)	3	C:99; D: 98; F: 60
MHBD disorder	1	C: 133
Hartnup disease	1	E: 69
MTHFR deficiency	1	B: 67
X-linked adrenoleukodystrophy	1	E: 72
Aicardi-Goutieres syndrome	1	C: 163
Other	16	
Pontocerebellar hypoplasia	5	A: 226; C: 102, 139; D: 96; E: 44
Rett syndrome	5	C: 165; D: 95; E: 79; F: 46, 57
Primary dystonia DYT negative	2	E: 72; F: 25
Dravet syndrome	1	C: 141
Cortical dysplasia	1	A: 363
Steinert dystrophy	1	A: 210
Congenital myasthenia	1	B: 193
Congenital conditions not etiologically determined	64	
Epileptic encephalopathy	19	A: 398; B:189, 183, 154; C: 152, 121, 134, 164, 169, 149, 162, 110; D: 77, 73, 74, 83; F: 28, 32, 50
Motor disturbances	10	C: 137, 111, 157, 104, 166; D: 97; F: 31, 36, 50, 6
Epilepsy	12	A: 273; C: 114, 108, 115, 118; D: 90, 105, 95, 93, 97, 63
Psychomotor delay	10	C: 122, 135, 146, 108, 130, 148, 133; D:102; F: 44, 50
Leukodystrophies of unknown etiology	8	C: 144, 113, 160, 159; D: 90, E: 65
Neuropsychiatric disturbances	5	C: 100; D: 103; E: 81, 74; F:58

Reference values: A (0–30 days): 428–1,122; B (1–5 months): 217–1,142; C (6 months–2 years): 170–490; D (3–6 years): 106–316; E (7–10 years): 87–366; F (11–16 years): 63–185

hypoplasia and Rett syndrome. Among patients with genetic and/or congenital conditions without a definitive diagnosis, 10 patients presented a clinical picture characterized predominantly by motor disturbances, 10 patients had a nonspecific psychomotor delay, another 8 patients had a complex clinical picture associated with MRI findings suggestive of leukodystrophy, and, finally, 5 patients presented neuropsychiatric disturbances including autism spectrum disorders and severe behavioral problems.

In Table 1, 5-HIAA values are expressed for each group of patients. Levels appeared to be extremely and particularly low in the first month of life and in patients presenting pontocerebellar hypoplasia or epilepsy.

Molecular studies in the low 5-HIAA study group

Five patients were selected for TPH2 molecular analysis (Table 2) based on the following clinical criteria: (1)

Table 2 Clinical and biochemical data of patients analyzed for *TPH2* gene mutations

N/ Sex	Diagnostic group	Age (years)	HIAA mean (NV)	HVA mean (NV)	Ratio	Epilepsy	Psychomotor delay	Abnormal movements	Magnetic resonance imaging	Follow-up (months)
1/F	Psychomotor delay	13	50 (63–185)	208 (156–410)	4.16	N	Y	N	Normal	18
2/F	Psychomotor delay	0.75	130 (170–490)	338 (344–906)	2.60	N	Y	N	Normal	21
3/F	Epileptic encephalopathy	2	77 (170–490)	335 (344–906)	4.35	Y	Y	N	Normal	17
4/M	Movement disorders	1	104 (170–490)	371 (344–906)	3.57	N	Y	Dystonia	Paramagnetic basal ganglia and deep white matter iron deposition	33
5/F	Autism spectrum disorder	2	100 (170–490)	452 (344–906)	4.52	N	Y	N	Normal	39

NV Normal values, Y yes, N no

absence of etiological diagnosis; (2) very severe unexplained symptoms; and (3) presence of striking neuropsychiatric/behavior abnormalities (behavior disturbances have been described in TPH2 knock-out mice).

Only previously reported single nucleotide polymorphisms and a 3-bp intronic deletion located more than 50 nucleotides upstream from the end of exon 1 in the *TPH2* gene (c.105+56_105+58delTCT) were found.

Biochemical correlations

Biochemical data were available for the whole group of 606 patients that underwent lumbar puncture. The presence of low CSF 5-HIAA was significantly associated with low CSF HVA (chi-squared=58.69, $p=0.0001$), while it was not associated with low pterins and 5-MTHF, or high CSF lactate values.

Clinical and neuroimaging correlations

When trying to establish an association between low 5-HIAA and clinical features (the presence of epilepsy, microcephaly, psychomotor delay, and presence of movement disorders), no significant relationship was found. Concerning neuroimaging analysis, in 236 patients, neuroimages were not available. Regarding the other 370/606, a significant relationship was demonstrated between 5-HIAA deficit and brainstem MRI abnormalities (chi-squared=6.377; $p=0.012$).

Discussion

To our knowledge, this is the first study describing the frequency of secondary 5-HIAA abnormality in CSF among patients with different neurological disorders. This biochemical feature was present in about 20% of patients who underwent lumbar puncture in our hospital, at different ages and with different clinical pictures and diagnoses. The

majority (91%) represented congenital or genetically determined disorders. This finding reflects the high vulnerability of serotonergic pathways due to their broad origins in the whole hindbrain and their diffuse innervation.

Our first study focused on secondary neurotransmitter deficiencies and involved 56 infants with different neurological disorders. We found that newborn patients with severe motor disturbances or disorders causing MRI abnormalities were more likely to have these alterations (García-Cazorla et al. 2007). In particular, 5-HIAA deficiency was associated with cortical brain atrophy. In the present study, we concentrated on 5-HIAA and analyzed a larger sample of patients with a wide age range.

Some clinical and diagnostic groups appeared to be particularly frequent. Patients with IEM accounted for 22.4% of the total. Most of them were affected by mitochondrial disorders, which are likely to produce abnormal neurotransmission given that this is an energetically demanding process. Indeed, we previously described five patients with mitochondrial disorders mimicking neurotransmitter disorders (García-Cazorla et al. 2008). 5HT is involved in the control of behavior and mood modulation. This particular vulnerability of serotonin in mitochondrial disorders could translate into the strong trend towards depression and mood disturbances that is found in these energetic deficiencies.

Other IEM found were quite heterogeneous and belong to different pathophysiological categories. Low levels of 5-HIAA could be due here to diverse neurobiological processes. Anatomical serotonergic innervation could explain this finding in our patients with pontocerebellar hypoplasias, other brainstem abnormalities, and Niemann-Pick type C. In IEM presenting with white matter abnormalities such as X-linked adrenoleukodystrophy, Alexander disease, and MTHFR deficiency, dysfunctional oligodendrocytes could contribute to abnormal levels of serotonin metabolites at the synapse, as they participate in neurotransmitter homeostasis (Ohno et al. 2007). Low 5-HIAA levels were also found in different organic acidurias. In these disorders, impairment of brain

energy, blood-brain barrier transport, and astroglial communication might contribute to neurotransmitter imbalance (Kölker et al. 2008).

Concerning primary defects in biogenic amine metabolism, 10 enzyme deficiencies have been described to date (Pons 2009). However, no pathogenetic mutations of the *TPH2* gene have as yet been found. Studies on *TPH2* $-/-$ mice confirmed that *TPH2* is the major gene responsible for central serotonergic projections, while peripheral 5HT is produced by *TPH1*. *TPH2*-derived 5HT is involved in the regulation of behavior and autonomic pathways but is not essential for adult life (Alenina et al. 2009).

A possible new neurodevelopmental syndrome related to 5HT pathway and responding to 5-hydroxytryptophan was described in 2001 (Ramaekers et al. 2001). However, *TPH2* gene analysis was normal in all five patients. We performed mutation screening of *TPH2* gene in five patients presenting a selective 5-HIAA deficit, but no pathogenetic mutations were found. In all likelihood, other mechanisms such as regulatory genes, transcriptional factors, or 5HT transporters are involved in determining a reduced 5HT turn-over.

Beyond metabolic diseases, in our series, low CSF 5-HIAA values were found in different neurological conditions. Patients with epileptic encephalopathy and epilepsy constituted an important group. Alterations of 5-HIAA have been reported in progressive myoclonic epilepsies, infantile spasms, and burst suppression pattern-associated disorders (Duarte et al. 2008). However, these results have been controversial (Langlais et al. 1991; Airaksinen et al. 1992) and an association between biogenic amines and antiepileptic drugs has not been excluded in previous studies (García-Cazorla et al. 2007; Assmann et al. 2002).

Regarding movement disorders, results are also controversial. Reduced 5-HIAA levels were previously reported in idiopathic dystonia and dopa nonresponsive dystonia (Naumann et al. 1996; Assmann et al. 2002). In our study, patients with extrapyramidal disorder did not seem to be frequently affected by 5-HIAA deficiency. In particular, two of seven patients with *DYT 1* negative primary dystonia showed HVA deficit and another patient with generalized progressive secondary dystonia showed very low HVA levels combined with HIAA deficiency. In our experience, secondary HVA deficiency is more frequently associated with severe motor impairment or perinatal asphyxia manifesting choreodystonia and basal ganglia abnormalities (García-Cazorla et al. 2007). However in a series of 448 young patients (Van Der Heyden et al. 2003), no correlation between low CSF HVA concentration and clinical symptoms or specific abnormalities at neuroimaging was found.

The close link existing between 5HT and dopamine in the brain, both at the biochemical and anatomical levels, may also explain the high association that we found between reduced 5-HIAA and reduced HVA. This result is in agreement with

those previously reported (Hyland et al. 1993). Moreover, as already described (García-Cazorla et al. 2007), patients with low 5-HIAA levels often suffered from neurometabolic or progressive disorders, most likely impairing dopamine metabolism as well.

From a diagnostic point of view, patients with isolated 5-HIAA deficit did not seem to differ from patients with associated HVA/HIAA deficiency (data not shown). However, all the patients with neuropsychiatric disturbances presented an isolated 5-HIAA deficiency. This is an interesting fact, given that disturbance in 5HT metabolism in childhood has also been suggested in autism, impulsive disorders, and depression (Zhang et al. 2005; Walitza et al. 2005). Another interesting consideration is that in AADC deficiency, an inborn error affecting both the dopaminergic and serotonergic pathway, patients may manifest with pervasive developmental disorders (Pons 2009). In adults, low CSF 5-HIAA concentration has been associated with suicidal behavior, schizophrenia, personality disorder, and certain impulse control disorders (Placidi et al. 2001). However, as psychiatric disorders in children do not constitute a clinical indication for lumbar puncture, the frequency of this biochemical alteration in these patients is not known.

In conclusion, low CSF 5-HIAA concentration was a common biochemical finding among patients with congenital and genetic neurological conditions. Regarding metabolic diseases, mitochondrial disorders seem especially vulnerable, as well as those involving the cerebellum, white matter, and organic acidurias. Due to serotonin's neurotrophic role, and in order to ameliorate neurological symptoms, a supplementary treatment with 5-hydroxytryptophan may be advisable in these conditions. Among patients without etiological diagnosis, epileptic encephalopathies and neuropsychiatric symptoms were commonly observed. No primary genetic deficiencies in 5HT metabolism (disease-causing mutations in the *TPH2* gene) could be demonstrated.

Acknowledgments We greatly appreciate the collaboration of the patients and their families in the study. CIBERER is an initiative of the ISCIII (MICINN, Spain), and part of this work resulted from an Intramural Project between CIBERER Units 703 and 736. This work was funded by the grants FIS PS09/01132 and FIS PI070548. R.A. is supported by the Programa de Intensificación de Actividad Investigadora of FIS.

References

- Airaksinen E, Tuomisto L, Riikonen R (1992) The concentrations of GABA, 5-HIAA and HVA in the cerebrospinal fluid of children with infantile spasms and the effects of ACTH treatment. *Brain Dev* 14:386–390
- Alenina N, Kiric D, Todiras M et al. (2009) Growth retardation and altered autonomic control in mice lacking brain serotonin. *Proc Nat Acad Sci USA* 105:10332–10337

- Assmann B, Kohler M, Hoffman G, Heales S, Surtees R (2002) Selective decrease in central nervous system serotonin turnover in children with dopa-nonresponsive dystonia. *Pediatr Res* 52:91–94
- Duarte S, Sanmarti F, Gonzalez V et al. (2008) Cerebrospinal fluid pterins and neurotransmitters in early severe epileptic encephalopathies. *Brain Dev* 30:106–111
- García-Cazorla A, Serrano M, Pérez-Dueñas B et al. (2007) Secondary abnormalities of neurotransmitters in infant with neurological disorders. *Dev Med Child Neurol* 49:740–744
- García-Cazorla A, Duarte S, Serrano M et al. (2008) Mitochondrial diseases mimicking neurotransmitter defects. *Mitochondrion* 8:273–278
- Herlenius E, Lagercrantz H (2001) Neurotransmitters and neuro-modulators during early human development. *Early Hum Dev* 65:21–37
- Hylland K, Surtees RA, Heales SJ, Bowron A, Howells DW, Smith I (1993) Cerebrospinal fluid concentrations of pterins and metabolites of serotonin and dopamine in a pediatric reference population. *Pediatr Res* 34:10–14
- Kölker S, Sauer SW, Hoffmann GF, Müller I, Morath MA, Okun JG (2008) Pathogenesis of CNS involvement in disorders of amino and organic acid metabolism. *J Inherit Metab Dis* 31:194–204
- Langlais PJ, Wardlow ML, Yamamoto H (1991) Changes in CSF neurotransmitters in infantile spasms. *Pediatr Neurol* 7:440–445
- Naumann M, Gotz M, Reiners K, Lange KW, Riederer P (1996) Neurotransmitters in CSF of idiopathic adult-onset dystonia: reduced 5HIA levels as evidence of impaired serotonergic metabolism. *J Neural Transm* 103:1083–1091
- Ohno Y, Hibino H, Lossin C, Inanobe A, Kurachi Y (2007) Inhibition of astroglial Kir4.1 channels by selective serotonin reuptake inhibitors. *Brain Res* 1178:44–51
- Ormazabal A, García-Cazorla A, Fernandez Y, Fernandez-Alvarez E, Campistol J, Artuch R (2005) HPLC with electrochemical and fluorescence detection procedures for the diagnosis of inborn errors of biogenic amines and pterins. *J Neurosci Methods* 142:153–158
- Placidi GP, Oquendo MA, Malone KM, Huang YY, Ellis SP, Mann JJ (2001) Aggressivity, suicide attempts, and depression: relationship to cerebrospinal fluid monoamine metabolite levels. *Biol Psychiatry* 50:783–791
- Pons R (2009) The phenotypic spectrum of paediatric neurotransmitter diseases and infantile parkinsonism. *J Inherit Metab Dis* 32:321–332
- Ramaekers VT, Senderek J, Häusler M et al (2001) A novel developmental syndrome responsive to 5-hydroxytryptophan and carbidopa. *Mol Genet Metab* 73:179–187
- Van Der Heyden JC, RotteveelJJ, Wevers RA (2003) Decreased homovanillic acid concentrations in cerebrospinal fluid in children without a known defect in dopamine metabolism. *Eur J Paediatr Neurol* 7(1):31–37
- Walitza S, Renner TJ, Dempfle A et al. (2005) Transmission disequilibrium of polymorphic variants in the tryptophan hydroxylase-2 gene in attention-deficit/hyperactivity disorder. *Mol Psychiatry* 10:1126–1132
- Zhang X, Gainetdinov RR, Beaulieu JM et al. (2005) Loss-of-function mutation in tryptophan hydroxylase-2 identified in unipolar major depression. *Neuron* 45:11–16